Scenesse Generic Name & Formulations
Afamelanotide 16mg; per implant; for SC use.
Melanocortin receptor agonist.
Implant (in vial)—1
To increase pain free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria.
Scenesse Dosage and Administration
See full labeling. Use an SFM implantation cannula or other suitable devices. ≥18yrs: Insert 1 implant subcutaneously above the anterior supra-iliac crest every 2 months.
<18yrs: not established.
Scenesse Boxed Warnings
Should be administered by an experienced health care provider. Pre-existing nevi and ephelides. Monitor skin pigmentary lesions; perform full body skin exam twice yearly. Advise patients to maintain sun and light protection measures during treatment to prevent phototoxic reactions. Pregnancy. Nursing mothers.
Scenesse Adverse Reactions
Implant site reaction, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory tract infection, non-acute porphyria, skin irritation; skin pigmentation/darkening.
Scenesse Clinical Trials
Scenesse Patient Counseling